Buchumschlag

Pragmatic Low‐Dose Oral Immunotherapy for Preschool Children With Peanut Allergy: A Randomised Controlled Trial

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Michael O'Sullivan, Rachael Wallace, Samantha Thomas, Alyssa Godfrey, Natasha Bear, Bhaumik Mevavala, Sarah Miller, Ingrid Roche, Samara Baldwin, Jessica R. Metcalfe
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Clinical & Experimental Allergy
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Developing a Standardised National Model of Care for Treatment of Peanut Allergy in Infants: The ADAPT Peanut Oral Immunotherapy Program
von: T. W. Brettig, et al.
Veröffentlicht: (2025)

Oral Immunotherapy of Peanut Allergy: A Critical Role for Gut‐Associated Immunity
von: A. Kuehn, et al.
Veröffentlicht: (2025)

Correspondence: First Peanut ( Arachis hypogaea ) Allergen Oral Immunotherapy Product Out of Sale—A Major Drawback for Food Allergy Immunotherapy?
von: S. Arasi, et al.
Veröffentlicht: (2026)

Oral Peanut Immunotherapy With Butyrate Adjuvant ( OPIA ) in Children: A Randomised, Controlled Trial
von: Peter S. Hsu, et al.
Veröffentlicht: (2025)

Colostrum as a Protective Factor Against Peanut Allergy: Evidence From a Birth Cohort
von: Maheshwar Bhasin, et al.
Veröffentlicht: (2025)

Allergen‐Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 Years
von: Sarah E. Ashley, et al.
Veröffentlicht: (2024)

Low‐Dose Intralymphatic Immunotherapy for Grass Pollen Allergy is Both Safe and Effective
von: Bjarke Hviid‐Vyff, et al.
Veröffentlicht: (2025)

Oral and Gut Microbial Hubs Associated With Reaction Threshold Interact With Circulating Immune Factors in Peanut Allergy
von: Lingdi Zhang, et al.
Veröffentlicht: (2025)

Efficacy and Safety of Ligelizumab in Individuals With Confirmed Peanut Allergy
von: Philippe Bégin, et al.
Veröffentlicht: (2026)

The Conversation on Oral Immunotherapy for Preschool Children Must Continue
von: Paxton Loke
Veröffentlicht: (2025)

Systematic Review and Meta‐Analysis of Oral Immunotherapy Effect on Food Allergy‐Related Quality of Life
von: Sophie A. Rosser, et al.
Veröffentlicht: (2025)

Fixed Very‐Low‐Dose Oral Immunotherapy in Infants and Toddlers With Low‐Threshold Egg, Milk or Wheat Allergy: A Prospective Cohort Study
von: Katsumasa Kitamura, et al.
Veröffentlicht: (2026)

Whole Blood Transcriptomics Identifies Differences in Innate Immune Pathway Expression in Infants at Risk for Peanut Allergy
von: Abigail Lang, et al.
Veröffentlicht: (2024)

Evaluation of Intestinal Permeability Using Serum Biomarkers in Learning Early About Peanut Allergy Trial
von: Ozge Nur Aktas, et al.
Veröffentlicht: (2025)

Safety and Efficacy of Very Low‐Dose Multi‐Nut Oral Immunotherapy in Children
von: Julia E. M. Upton, et al.
Veröffentlicht: (2025)

One Year of Oral Immunotherapy Impacts the Gut Microbiota and Plasma Metabolome of Peanut‐Allergic Young Children
von: Isabella Badolati, et al.
Veröffentlicht: (2024)

Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open‐Label, Phase II Study
von: Sayantani B. Sindher, et al.
Veröffentlicht: (2024)

Design of the Intervention to Reduce Early Peanut Allergy in Children ( iREACH ): A practice‐based clinical trial
von: Lucy A. Bilaver, et al.
Veröffentlicht: (2024)

Algorithms in Allergy: General Allergen Molecule‐Based Algorithm for Allergen‐Specific Immunotherapy
von: Huey‐Jy Huang, et al.
Veröffentlicht: (2026)

Autoclaved Peanuts Exhibit Reduced Immunoglobulin E Binding and Improved Oral Tolerability
von: Casey G. Cohen, et al.
Veröffentlicht: (2026)

A Pilot Randomised Controlled Dose‐Ranging Trial of Ant Venom Immunotherapy With and Without Delta‐Inulin Adjuvant
von: Thanh‐Thao Adriana Le, et al.
Veröffentlicht: (2026)

Adverse Effects of Dupilumab, Effects of Peanut OIT on the Gut Microbiome and Allergy Training in the United Kingdom
von: Mohamed H. Shamji, et al.
Veröffentlicht: (2025)

Correlation and Agreement Between Parent‐Report and Self‐Report Food Allergy Quality of Life Questionnaires After Oral Immunotherapy
von: Sophie A. Rosser, et al.
Veröffentlicht: (2026)

The Drop of Allergen Immunotherapy for Respiratory Allergy in Italy: An Assessment of Sales
von: Mattia Giovannini, et al.
Veröffentlicht: (2025)

Preventive Application of House Dust Mite‐Sublingual Immunotherapy Induces Blocking Antibodies in Sensitized Preschool Children
von: Varsha Dwivedi, et al.
Veröffentlicht: (2026)

Prevalence Survey on Oral Allergy Syndrome in Patients With Seasonal Allergic Rhinitis in Yamanashi, Japan
von: Ayumi Shimamura, et al.
Veröffentlicht: (2024)

Questionnaire Survey on Loquat‐Induced Oral Allergy Syndrome in School Children in Yamanashi, Japan
von: Ayumi Shimamura, et al.
Veröffentlicht: (2025)

Making Peanuts Safer: Autoclaving as a Heat and Pressure Strategy to Increase Peanut Tolerability
von: Damian Stodulski, et al.
Veröffentlicht: (2026)

Neonatal BCG Vaccination for Prevention of Allergy in Infants: The MIS BAIR Randomised Controlled Trial
von: Nicole L. Messina, et al.
Veröffentlicht: (2024)

Peanut Component‐Specific IgE and IgG4 Are Modulated by Sublingual Immunotherapy and Are Associated With Remission in 1–4‐Year‐Old Children
von: Neel Singh, et al.
Veröffentlicht: (2025)

Comparison Between a Rush and a Conventional Oral Immunotherapy Protocol to Treat Cow's Milk and Hen's Egg Allergy. CompITO Study Methodology
von: Itziar Eusebio‐Cartagena, et al.
Veröffentlicht: (2025)

Occupational Mite Allergy and Asthma: An EAACI Task Force Report
von: Hille Suojalehto, et al.
Veröffentlicht: (2025)

Adherence to Grass Pollen Allergen Immunotherapy and Allergy Medication Use in Patients With Allergic Rhinitis
von: Morten Borg, et al.
Veröffentlicht: (2025)

Wildfires and Respiratory Allergy
von: Gennaro D'Amato, et al.
Veröffentlicht: (2025)

Effects of Butyrylated High Amylose Maize Starch ( HAMSB ) as an Adjuvant for Oral Immunotherapy
von: Duan Ni, et al.
Veröffentlicht: (2025)

Biphasic Effects on Allergen‐Specific Type 2 Memory B Cells Over 18 Months Sublingual Immunotherapy for House Dust Mite Allergy
von: Lin Hsin, et al.
Veröffentlicht: (2026)

Codfish Oral Immunotherapy in Children Aged 2–10: Randomized Placebo‐Controlled Study
von: Agnes Sze‐yin Leung, et al.
Veröffentlicht: (2026)

Algorithms in Allergy: Hereditary Angioedema
von: Konrad Bork, et al.
Veröffentlicht: (2026)

Point‐of‐Care Blood Eosinophils to Predict Preschool Wheeze Attacks
von: Kushalinii Hillson, et al.
Veröffentlicht: (2025)

Oral Immunotherapy Induces Shift in lncRNA Expression Modulating Allergen‐Specific Immune Responses
von: Olivia Liong, et al.
Veröffentlicht: (2025)